Figures & data
Figure 1 Study design.
![Figure 1 Study design.](/cms/asset/728062d6-8aa4-4b0f-ba2d-be4ec7b86973/dcop_a_12163822_f0001_b.jpg)
Figure 2 Patient disposition. aICD codes for COPD are shown in Table S1. bICD codes for asthma included ICD-9-CM: 493.xx; ICD-10-CM: J45.3, J45.4, J45.5, J45.9. cHigh-comorbidity patients were defined as having a pre-index Quan-CCI score ≥3. dHigh-cost patients were defined as those with pre-index all-cause medical costs exceeding the 80th percentile of the cost distribution in the overall IMT COPD population.
![Figure 2 Patient disposition. aICD codes for COPD are shown in Table S1. bICD codes for asthma included ICD-9-CM: 493.xx; ICD-10-CM: J45.3, J45.4, J45.5, J45.9. cHigh-comorbidity patients were defined as having a pre-index Quan-CCI score ≥3. dHigh-cost patients were defined as those with pre-index all-cause medical costs exceeding the 80th percentile of the cost distribution in the overall IMT COPD population.](/cms/asset/d51c63ae-675a-4fd4-a9d0-db522a4ab75e/dcop_a_12163822_f0002_c.jpg)
Table 1 Pre-Index Patient Characteristics for UMEC/VI versus FP/SAL, B/F, and TIO Matched Cohorts
Table 2 On-Treatment Medical Costs PPPY for UMEC/VI versus FP/SAL, B/F, and TIO Matched Cohorts
Figure 3 Kaplan–Meier curves for time-to-first severe exacerbation during the on-treatment period for (A) UMEC/VI versus FP/SAL, (B) UMEC/VI versus B/F, and (C) UMEC/VI versus TIO matched cohorts. aNumber of patients still observed at the specific point in time. bSevere COPD-related exacerbation defined as an inpatient hospitalization with a diagnosis code for COPD in the primary position.
![Figure 3 Kaplan–Meier curves for time-to-first severe exacerbation during the on-treatment period for (A) UMEC/VI versus FP/SAL, (B) UMEC/VI versus B/F, and (C) UMEC/VI versus TIO matched cohorts. aNumber of patients still observed at the specific point in time. bSevere COPD-related exacerbation defined as an inpatient hospitalization with a diagnosis code for COPD in the primary position.](/cms/asset/b798aba3-b7bc-41b4-bb87-5c7b5cc1d78f/dcop_a_12163822_f0003_c.jpg)
Table 3 Rate of on-Treatment COPD-Related Severe Exacerbations for UMEC/VI versus FP/SAL, B/F, and TIO and Matched Cohorts